Clinical Trials Logo

Clinical Trial Summary

This is a single-center prospective pilot study involving the ophthalmology and medical genetics departments of the Montpellier University Hospital, and the proteomics platform of the Montpellier University Hospital. 5 patients with PAX6 pathogenic variation will be included in order to determine the proteomic profile in a tear sample associated with different pathogenic variations of the PAX6 gene. Participation in the study for the patients consists of a single visit with an ophthalmological examination and a tear collection.


Clinical Trial Description

The transcription factor PAX6 is required for the normal development of all elements constituting the eyeball, including the lacrimal gland. In patients with PAX6 gene mutations, the cornea presents a limbal anomaly that has been evolving since childhood and is responsible for variable damage. It evolves from a simple peripheral keratopathy to an advanced stage with complete corneal opacification and fibrosis. Chronic inflammation, associated with tear film damage is very common and promotes keratopathy. The current treatment of dry eye in patients with ocular malformation related to a PAX6 mutation is non specific: it aims to palliate the quantitative tear defect and uses tear substitutes, cyclosporine eye drops, meatus plugs, scleral lenses. The identification of specific qualitative abnormalities constitutes the indispensable preliminary step necessary in order to be able to consider in the long term an adapted treatment, of tear protein supplementation, aiming at preserving the cornea of patients with an ocular malformation related to a PAX6 gene mutation. In this study, patients will be recruited from the active file of patients and patients previously treated in the ophthalmology or medical genetics departments of Montpellier University Hospital for an ocular malformation related to a PAX6 mutation. Participation in the study will consist of a single visit of up to 3 hours. During the pre-inclusion visit, the existence of a pathogenic variation of the PAX6 gene identified in each patient will be verified. Once the inclusion is achieved, the same day, it is planned to: - data collection: demographic (age, sex), clinical (weight, height, head circumference, blood pressure, associated neurodevelopmental disorder, neurological examination, extraocular damage, description of the ocular malformation, previous surgical interventions) and genetic (description of the pathogenic variation of the PAX6 gene), - an ophthalmological examination, - the collection of tears by Schirmer strip (2 to 4 mm) will be performed by the ophthalmologist. The data for each protein in the spectrum will be compared with the previously established reference proteomic profile range. Significant variations (50% change) will be retained. The discovery of tear film abnormalities in the pathophysiological context of a PAX6 gene alteration will allow a better understanding of the progressive tear and corneal damage in these complex ocular malformations. This is an essential preliminary step in the perspective of a better management of the patients, by the creation of specific adapted eye drops allowing to palliate more specifically the identified anomalies, following the example of the treatment by eye drops containing NGF developed in the United States in order to treat the attacks of the corneal innervation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05562115
Study type Interventional
Source University Hospital, Montpellier
Contact Marjolaine WILLEMS, PH
Phone 04 67 33 65 64
Email m-willems@chu-montpellier.fr
Status Recruiting
Phase N/A
Start date February 9, 2023
Completion date August 2024

See also
  Status Clinical Trial Phase
Completed NCT00758108 - Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Recruiting NCT05400590 - Comparison of the Healing Properties on Corneal Cells of Groth Factor-enriched Plasma and Autologous Serum From Aniridia Patients
Recruiting NCT05044598 - RAFT - Clinical Trial of RAFT for Aniridia Related Keratopathy Phase 1/Phase 2
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT00001161 - Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens N/A
Enrolling by invitation NCT03461978 - Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures N/A
Recruiting NCT05954403 - National Cohort on Congenital Defects of the Eye
Completed NCT02647359 - Study of Ataluren in Participants With Nonsense Mutation Aniridia Phase 2
Completed NCT03581864 - Clinical Outcomes of Implantationof Black Diaphragm Intraocular Lens in Complete Aniridia and Aphakia Due to Posttraumatic Eye Rupture
Completed NCT00265590 - Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia N/A
Withdrawn NCT04117880 - A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia Phase 2
Active, not recruiting NCT00503893 - Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies
Completed NCT01644552 - Positive Angle Kappa
Completed NCT00812708 - Clinical Evaluation of Morcher Artificial Iris Diaphragms N/A